Skip to main content
This website is moving to Springer Nature Link. Search Explore journals Get published About BMC My account Search all BMC articles Search

V体育平台登录 - Lung Cancer Awareness Month

Empowering Lung Cancer Awareness Month: Dive into a retrospective collection from across our open access titles of informative articles and insights that illuminate the importance of early detection, treatment innovations, and support networks in the battle against lung cancer, highlighting the collective efforts to raise awareness and improve outcomes for individuals and their families.   VSports app下载.

The following journals are participating in this retrospective collection: Journal of Hematology & Oncology, Molecular Cancer, Journal of Experimental and Clinical Cancer Research, Biomarker Research, Cancer Imaging, Experimental Hematology & Oncology, Radiation Oncology, and Cancer Cell International V体育官网.  .

  1. To compare the genomic testing based on specimens obtained from percutaneous core-needle biopsy (CNB) before and immediately after coaxial microwave ablation (MWA) in solid non-small cell lung cancer (NSCLC), VSports手机版. .

    Authors: Sheng Xu, Lei He, Jing Qi, Fan-Lei Kong, Zhi-Xin Bie, Yuan-Ming Li, Zheng Wang and Xiao-Guang Li
    Citation: Cancer Imaging 2023 23:93
    Content type: Research article Published on:

  2. Small cell lung cancer (SCLC) has an exceptionally poor prognosis; as most of the cases are initially diagnosed as extensive disease with hematogenous metastasis. Therefore, the early diagnosis of SCLC is very V体育安卓版. .

    Authors: Dong Ha Kim, Hyojeong Park, Yun Jung Choi, Kyungtaek Im, Chae Won Lee, Da-Som Kim, Chan-Gi Pack, Hyun-Yi Kim, Chang-Min Choi, Jae Cheol Lee, Wonjun Ji and Jin Kyung Rho
    Citation: Biomarker Research 2023 11:80
    Content type: Research Published on:

  3. Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence. V体育ios版.

    Authors: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego and Luis Paz-Ares
    Citation: Journal of Hematology & Oncology 2023 16:66
    Content type: Review Published on:

  4. VSports注册入口 -

    There is no consensus on 3-dimensional (3D) quantification method for solid component within part-solid nodules (PSNs). This study aimed to find the optimal attenuation threshold for the 3D solid component pro. VSports最新版本.

    Authors: Jieke Liu, Chaolian Xie, Yong Li, Hao Xu, Changjiu He, Haomiao Qing and Peng Zhou
    Citation: Cancer Imaging 2023 23:65
    Content type: Research article Published on:

  5. Current studies indicate that fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography ([18F]FDG PET/CT) is the most accurate imaging modality for the detection of relapsed locally advance V体育平台登录. .

    Authors: Alexander Brose, Kerstin Michalski, Juri Ruf, Marco Tosch, Susanne M. Eschmann, Mathias Schreckenberger, Jochem König, Ursula Nestle and Matthias Miederer
    Citation: Cancer Imaging 2023 23:45
    Content type: Research article Published on:

  6. Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving VSports注册入口. The width and depth of clinical trials have also dramatically improved in an unpr. .

    Authors: Si-Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si-Yang Liu, Yangqiu Li and Yi-Long Wu
    Citation: Journal of Hematology & Oncology 2023 16:40
    Content type: Review Published on:

  7. ADJUVANT-CTONG1104 reported a favorable survival outcome from adjuvant gefitinib treatment over chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients. However, heterogeneous benefit from EGFR-TK V体育官网入口. .

    Authors: Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu and Yangqiu Li
    Citation: Biomarker Research 2023 11:26
    Content type: Correspondence Published on:

  8. To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monot. VSports在线直播.

    Authors: Kyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Shin Yanagisawa, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka…
    Citation: Cancer Imaging 2023 23:23
    Content type: Research article Published on:

  9. Although some studies have assessed the correlation between computed tomography (CT) features and anaplastic lymphoma kinase (ALK) rearrangement in patients with non-small-cell lung cancer (NSCLC), few have fo...

    Authors: Xiaoming Hou, Han Chen, You Liu, Sandong Gong, Meizi Zhudai and Leilei Shen
    Citation: Cancer Imaging 2023 23:20
    Content type: Research article Published on:

  10. Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therap...

    Authors: Aritraa Lahiri, Avik Maji, Pravin D. Potdar, Navneet Singh, Purvish Parikh, Bharti Bisht, Anubhab Mukherjee and Manash K. Paul
    Citation: Molecular Cancer 2023 22:40
    Content type: Review Published on:

  11. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations. Approximately half of the patients with EGFR-muta...

    Authors: Chia-Feng Lu, Chien-Yi Liao, Heng-Sheng Chao, Hwa-Yen Chiu, Ting-Wei Wang, Yen Lee, Jyun-Ru Chen, Tsu-Hui Shiao, Yuh-Min Chen and Yu-Te Wu
    Citation: Cancer Imaging 2023 23:9
    Content type: Research article Published on:

  12. Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patient...

    Authors: Luis A. Godoy, Joy Chen, Weijie Ma, Jag Lally, Kyra A. Toomey, Prabhu Rajappa, Roya Sheridan, Shirish Mahajan, Nicholas Stollenwerk, Chinh T. Phan, Danny Cheng, Robert J. Knebel and Tianhong Li
    Citation: Biomarker Research 2023 11:7
    Content type: Review Published on:

  13. Locally advanced non-small cell lung cancer (NSCLC) is frequent at diagnosis and requires multimodal treatment approaches. Neoadjuvant chemotherapy (NACT) followed by surgery is the treatment of choice for ope...

    Authors: Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasquier, Julian Sanz-Ortega…
    Citation: Journal of Hematology & Oncology 2022 15:178
    Content type: Research Published on:

  14. VSports在线直播 -

    Texture analysis derived from computed tomography (CT) can provide clinically relevant imaging biomarkers. Node-RADS is a recently proposed classification to categorize lymph nodes in radiological images. The ...

    Authors: Hans-Jonas Meyer, Benedikt Schnarkowski, Johanna Pappisch, Teresa Kerkhoff, Hubert Wirtz, Anne-Kathrin Höhn, Sebastian Krämer, Timm Denecke, Jakob Leonhardi and Armin Frille
    Citation: Cancer Imaging 2022 22:75
    Content type: Research article Published on:

  16. Definitive concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (LANSCLC) patients, but the treatment response and survival outcomes varied among these ...

    Authors: Nai-Bin Chen, Mai Xiong, Rui Zhou, Yin Zhou, Bo Qiu, Yi-Feng Luo, Su Zhou, Chu Chu, Qi-Wen Li, Bin Wang, Hai-Hang Jiang, Jin-Yu Guo, Kang-Qiang Peng, Chuan-Miao Xie and Hui Liu
    Citation: Radiation Oncology 2022 17:184
    Content type: Research Published on:

  17. Besides featured glucose consumption, recent studies reveal that cancer cells might prefer “addicting” specific energy substrates from the tumor microenvironment (TME); however, the underlying mechanisms remai...

    Authors: Tongyan Liu, Chencheng Han, Panqi Fang, Zhifei Ma, Xiaoxiao Wang, Hao Chen, Siwei Wang, Fanchen Meng, Cheng Wang, Erbao Zhang, Guozhang Dong, Hongyu Zhu, Wenda Yin, Jie Wang, Xianglin Zuo, Mantang Qiu…
    Citation: Journal of Hematology & Oncology 2022 15:141
    Content type: Research Published on:

  18. Circulating tumor DNA (ctDNA) has been proven as a marker for detecting minimal residual diseases following systemic therapies in mid-to-late-stage non-small-cell lung cancers (NSCLCs) by multiple studies. How...

    Authors: Siwei Wang, Ming Li, Jingyuan Zhang, Peng Xing, Min Wu, Fancheng Meng, Feng Jiang, Jie Wang, Hua Bao, Jianfeng Huang, Binhui Ren, Mingfeng Yu, Ninglei Qiu, Houhuai Li, Fangliang Yuan, Zhi Zhang…
    Citation: Journal of Hematology & Oncology 2022 15:137
    Content type: Correspondence Published on:

  19. Solid tumors subjected to intermittent hypoxia are characterized by resistance to chemotherapy and immune-killing by effector T-lymphocytes, particularly tumor-infiltrating Vγ9Vδ2 T-lymphocytes. The molecular ...

    Authors: Iris C. Salaroglio, Dimas Carolina Belisario, Muhlis Akman, Sofia La Vecchia, Martina Godel, Dario Pasquale Anobile, Giacomo Ortone, Sabrina Digiovanni, Simona Fontana, Costanzo Costamagna, Menachem Rubinstein, Joanna Kopecka and Chiara Riganti
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:243
    Content type: Research Published on:

  20. Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation i...

    Authors: Jun Lu, Jun Wu, Yuqing Lou, Qin Shi, Jun Xu, Lele Zhang, Wei Nie, Jie Qian, Yanan Wang, Yanwei Zhang, Jing Jiao, Xueyan Zhang, Wei Zhang, Huimin Wang, Tianqing Chu, Hua Zhong…
    Citation: Biomarker Research 2022 10:55
    Content type: Research Published on:

  21. This retrospective study was performed to evaluate the efficacy and toxicity of high-dose stereotactic body radiotherapy (SBRT) using a CyberKnife® for patients with stage I peripheral non-small cell lung canc...

    Authors: Yasuhiro Ryuno, Takanori Abe, Misaki Iino, Satoshi Saito, Tomomi Aoshika, Tomohiro Oota, Mitsunobu Igari, Ryuta Hirai, Yu Kumazaki, Kyoichi Kaira, Hiroshi Kagamu, Hironori Ishida, Shin-ei Noda and Shingo Kato
    Citation: Radiation Oncology 2022 17:128
    Content type: Research Published on:

  22. To examine long-term-survival of cT4 cN0/1 cM0 non-small-cell lung carcinoma (NSCLC) patients undergoing definitive radiochemotherapy (ccRTx/CTx) in comparison to the trimodality treatment, neoadjuvant radiochemo...

    Authors: Nika Guberina, Christoph Pöttgen, Martin Schuler, Maja Guberina, Georgios Stamatis, Till Plönes, Martin Metzenmacher, Dirk Theegarten, Thomas Gauler, Kaid Darwiche, Clemens Aigner, Wilfried E. E. Eberhardt and Martin Stuschke
    Citation: Radiation Oncology 2022 17:126
    Content type: Research Published on:

  23. Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistanc...

    Authors: Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh and Tetsuya Mitsudomi
    Citation: Journal of Hematology & Oncology 2022 15:79
    Content type: Research Published on:

  24. Multiple lines of evidence have demonstrated that circular RNAs (circRNAs) play oncogenic or tumor-suppressive roles in various human cancers. Nevertheless, the biological functions of circRNAs in small cell l...

    Authors: Jinghan Hua, Xiaolin Wang, Liying Ma, Jingxin Li, Guozhen Cao, Shaobo Zhang and Wenchu Lin
    Citation: Molecular Cancer 2022 21:123
    Content type: Research Published on:

  25. Despite tremendous success of molecular targeted therapy together with immunotherapy, only a small subset of patients can benefit from them. Chemotherapy remains the mainstay treatment for most of tumors inclu...

    Authors: Yao Jiang, Wei Huang, Xiaojiao Sun, Xiaozhou Yang, Youming Wu, Jiaojiao Shi, Ji Zheng, Shujie Fan, Junya Liu, Jun Wang, Zhen Liang, Nan Yang, Zhenming Liu and Yanyong Liu
    Citation: Journal of Hematology & Oncology 2022 15:73
    Content type: Correspondence Published on:

  26. Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictiv...

    Authors: Diego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, Murat Ak, Feliciano Barron, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara-Mejia, Christine B. Peterson, Mehmet E. Er, Vishal Peddagangireddy, Francesco Buemi, Brandon Cooper, Paolo Manca, Rena G. Lapidus, Ru-Ching Hsia…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:186
    Content type: Research Published on:

  27. Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic chang...

    Authors: Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu…
    Citation: Journal of Hematology & Oncology 2022 15:62
    Content type: Correspondence Published on:

  28. Previous studies have confirmed the oncogenic role of HMGB2 in various cancers, but the biological functions of HMGB2-derived circRNAs remain unknown. Thus, we intended to investigate the potential role of HMG...

    Authors: Ling-Xian Zhang, Jian Gao, Xiang Long, Peng-Fei Zhang, Xin Yang, Shu-Qiang Zhu, Xu Pei, Bai-Quan Qiu, Shi-Wei Chen, Feng Lu, Kun Lin, Jian Jun Xu and Yong-Bing Wu
    Citation: Molecular Cancer 2022 21:110
    Content type: Research Published on:

  29. Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in firs...

    Authors: Lin Zhang, Weihao Lin, Fengwei Tan, Ning Li, Qi Xue, Shugeng Gao, Yibo Gao and Jie He
    Citation: Biomarker Research 2022 10:23
    Content type: Review Published on:

  30. Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The discovery of epidermal growth factor receptor (EGFR) gene mutations and the development of EGFR tyrosine kinase inhibi...

    Authors: Jiabao Hou, Hongle Li, Shuxiang Ma, Zhen He, Sen Yang, Lidan Hao, Hanqiong Zhou, Zhe Zhang, Jing Han, Li Wang and Qiming Wang
    Citation: Biomarker Research 2022 10:21
    Content type: Review Published on:

  31. Lung cancer remains one of the major causes of cancer-related death globally. Recent studies have shown that aberrant m6A levels caused by METTL3 are involved in the malignant progression of various tumors, inclu...

    Authors: Chao Ma, Rui-Jie Ma, Kang Hu, Qi-Ming Zheng, Ye-Peng Wang, Nan Zhang and Zhi-Gang Sun
    Citation: Cancer Cell International 2022 22:133
    Content type: Review Published on:

  32. Autophagy has been found to be involved in the multidrug resistance (MDR) of cancers, but whether it is associated with resistance of small cell lung cancer (SCLC) has not been studied. Here, we hypothesized t...

    Authors: Tiezhi Li, Helin Zhang, Zhichao Wang, Shaolin Gao, Xu Zhang, Haiyong Zhu, Na Wang and Honglin Li
    Citation: Cancer Cell International 2022 22:120
    Content type: Primary research Published on:

  33. Online MR-guided radiotherapy (MRgRT) is a relatively novel advancement in the field of radiation oncology, ensuring superior soft-tissue visualisation, allowing for online plan adaptation to anatomical and fu...

    Authors: Chukwuka Eze, Elia Lombardo, Lukas Nierer, Yuqing Xiong, Maximilian Niyazi, Claus Belka, Farkhad Manapov and Stefanie Corradini
    Citation: Radiation Oncology 2022 17:43
    Content type: Short report Published on:

  34. Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). The mechanisms of osimertinib resistance need to be elucidated to determine...

    Authors: Xiaoying Wan, Boxiong Xie, Hui Sun, Weiqing Gu, Chunyan Wang, Qinfang Deng and Songwen Zhou
    Citation: Cancer Cell International 2022 22:83
    Content type: Primary research Published on:

  35. Approximately 50%–60% of secondary resistance to primary EGFR- tyrosine kinase inhibitors (TKI) therapy is caused by acquired p.Thr790Met (T790M) mutation; however, highly fragmented, low-quantity circulating tum...

    Authors: Boyeon Kim, Yoonjung Kim, Saeam Shin, Seung-Tae Lee, Jae Yong Cho and Kyung-A. Lee
    Citation: Cancer Cell International 2022 22:82
    Content type: Primary research Published on:

  36. Accurate predictions of tumor dissemination risks and medical treatment outcomes are critical to personalize therapy. Patient-derived xenograft (PDX) models in mice have demonstrated high accuracy in predictin...

    Authors: Zaheer Ali, Malin Vildevall, Gabriela Vazquez Rodriguez, Decky Tandiono, Ioannis Vamvakaris, Georgios Evangelou, Georgios Lolas, Konstantinos N. Syrigos, Alberto Villanueva, Michael Wick, Shenga Omar, Anna Erkstam, Julia Schueler, Anna Fahlgren and Lasse D. Jensen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:58
    Content type: Research Published on:

  37. Inflammation is a process that protects organs against various potentially harmful stimuli and enables repair. Dysregulated inflammation, however, damages tissues and leads to disease, including cancer. Cancer...

    Authors: Jun Zhang and Nirmal Veeramachaneni
    Citation: Biomarker Research 2022 10:5
    Content type: Review Published on:

  38. When genes responsible for normal embryonic development are abnormally expressed in adults, it can lead to tumor development. This can suggest that the same mechanism that controls embryonic differentiation ca...

    Authors: Jordi Canals, Alfons Navarro, Cristina Vila, Josep M. Canals, Tania Díaz, Melissa Acosta-Plasencia, Coralí Cros-Font, Bing Han, Yangyi He and Mariano Monzó
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:37
    Content type: Research Published on:

  39. Limited previous studies focused on the death and progression risk stratification of colorectal cancer (CRC) lung metastasis patients. The aim of this study is to construct a nomogram model combing machine lea...

    Authors: Renjie Wang, Weixing Dai, Jing Gong, Mingzhu Huang, Tingdan Hu, Hang Li, Kailin Lin, Cong Tan, Hong Hu, Tong Tong and Guoxiang Cai
    Citation: Journal of Hematology & Oncology 2022 15:11
    Content type: Letter to the Editor Published on:

  40. Primary lung cancer is one of the most common malignant tumors in China. Approximately 60% of lung cancer patients have distant metastasis at the initial diagnosis, so it is necessary to find new tumor markers...

    Authors: Wen Li, Ji-Bin Liu, Li-Kun Hou, Fei Yu, Jie Zhang, Wei Wu, Xiao-Mei Tang, Feng Sun, Hai-Min Lu, Jing Deng, Jie Bai, Juan Li, Chun-Yan Wu, Qin-Lu Lin, Zhong-Wei Lv, Gao-Ren Wang…
    Citation: Molecular Cancer 2022 21:25
    Content type: Review Published on:

  41. Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durval...

    Authors: Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo and Akito Hata
    Citation: Radiation Oncology 2022 17:7
    Content type: Research Published on:

  42. V体育官网入口 -

    N6-methyladenosine (m6A) has emerged as a significant regulator of the progress of various cancers. However, its role in lung adenocarcinoma (LUAD) remains unclear. Here, we explored the biological function and u...

    Authors: Yiming Xu, Dandan Lv, Chao Yan, Hua Su, Xue Zhang, Yangfeng Shi and Kejing Ying
    Citation: Cancer Cell International 2022 22:11
    Content type: Primary research Published on:

  1. To compare the genomic testing based on specimens obtained from percutaneous core-needle biopsy (CNB) before and immediately after coaxial microwave ablation (MWA) in solid non-small cell lung cancer (NSCLC), ...

    Authors: Sheng Xu, Lei He, Jing Qi, Fan-Lei Kong, Zhi-Xin Bie, Yuan-Ming Li, Zheng Wang and Xiao-Guang Li
    Citation: Cancer Imaging 2023 23:93
    Content type: Research article Published on:

  2. Small cell lung cancer (SCLC) has an exceptionally poor prognosis; as most of the cases are initially diagnosed as extensive disease with hematogenous metastasis. Therefore, the early diagnosis of SCLC is very...

    Authors: Dong Ha Kim, Hyojeong Park, Yun Jung Choi, Kyungtaek Im, Chae Won Lee, Da-Som Kim, Chan-Gi Pack, Hyun-Yi Kim, Chang-Min Choi, Jae Cheol Lee, Wonjun Ji and Jin Kyung Rho
    Citation: Biomarker Research 2023 11:80
    Content type: Research Published on:

  3. Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately, followed by rapid disease recurrence...

    Authors: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego and Luis Paz-Ares
    Citation: Journal of Hematology & Oncology 2023 16:66
    Content type: Review Published on:

  4. There is no consensus on 3-dimensional (3D) quantification method for solid component within part-solid nodules (PSNs). This study aimed to find the optimal attenuation threshold for the 3D solid component pro...

    Authors: Jieke Liu, Chaolian Xie, Yong Li, Hao Xu, Changjiu He, Haomiao Qing and Peng Zhou
    Citation: Cancer Imaging 2023 23:65
    Content type: Research article Published on:

  5. Current studies indicate that fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography ([18F]FDG PET/CT) is the most accurate imaging modality for the detection of relapsed locally advance...

    Authors: Alexander Brose, Kerstin Michalski, Juri Ruf, Marco Tosch, Susanne M. Eschmann, Mathias Schreckenberger, Jochem König, Ursula Nestle and Matthias Miederer
    Citation: Cancer Imaging 2023 23:45
    Content type: Research article Published on:

  6. V体育官网入口 -

    Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unpr...

    Authors: Si-Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si-Yang Liu, Yangqiu Li and Yi-Long Wu
    Citation: Journal of Hematology & Oncology 2023 16:40
    Content type: Review Published on:

  7. ADJUVANT-CTONG1104 reported a favorable survival outcome from adjuvant gefitinib treatment over chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients. However, heterogeneous benefit from EGFR-TK...

    Authors: Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu and Yangqiu Li
    Citation: Biomarker Research 2023 11:26
    Content type: Correspondence Published on:

  8. To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monot...

    Authors: Kyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Shin Yanagisawa, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka…
    Citation: Cancer Imaging 2023 23:23
    Content type: Research article Published on:

  9. Although some studies have assessed the correlation between computed tomography (CT) features and anaplastic lymphoma kinase (ALK) rearrangement in patients with non-small-cell lung cancer (NSCLC), few have fo...

    Authors: Xiaoming Hou, Han Chen, You Liu, Sandong Gong, Meizi Zhudai and Leilei Shen
    Citation: Cancer Imaging 2023 23:20
    Content type: Research article Published on:

  10. Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therap...

    Authors: Aritraa Lahiri, Avik Maji, Pravin D. Potdar, Navneet Singh, Purvish Parikh, Bharti Bisht, Anubhab Mukherjee and Manash K. Paul
    Citation: Molecular Cancer 2023 22:40
    Content type: Review Published on:

  11. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations. Approximately half of the patients with EGFR-muta...

    Authors: Chia-Feng Lu, Chien-Yi Liao, Heng-Sheng Chao, Hwa-Yen Chiu, Ting-Wei Wang, Yen Lee, Jyun-Ru Chen, Tsu-Hui Shiao, Yuh-Min Chen and Yu-Te Wu
    Citation: Cancer Imaging 2023 23:9
    Content type: Research article Published on:

  12. Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patient...

    Authors: Luis A. Godoy, Joy Chen, Weijie Ma, Jag Lally, Kyra A. Toomey, Prabhu Rajappa, Roya Sheridan, Shirish Mahajan, Nicholas Stollenwerk, Chinh T. Phan, Danny Cheng, Robert J. Knebel and Tianhong Li
    Citation: Biomarker Research 2023 11:7
    Content type: Review Published on:

  13. Locally advanced non-small cell lung cancer (NSCLC) is frequent at diagnosis and requires multimodal treatment approaches. Neoadjuvant chemotherapy (NACT) followed by surgery is the treatment of choice for ope...

    Authors: Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasquier, Julian Sanz-Ortega…
    Citation: Journal of Hematology & Oncology 2022 15:178
    Content type: Research Published on:

  14. Texture analysis derived from computed tomography (CT) can provide clinically relevant imaging biomarkers. Node-RADS is a recently proposed classification to categorize lymph nodes in radiological images. The ...

    Authors: Hans-Jonas Meyer, Benedikt Schnarkowski, Johanna Pappisch, Teresa Kerkhoff, Hubert Wirtz, Anne-Kathrin Höhn, Sebastian Krämer, Timm Denecke, Jakob Leonhardi and Armin Frille
    Citation: Cancer Imaging 2022 22:75
    Content type: Research article Published on:

  16. Definitive concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (LANSCLC) patients, but the treatment response and survival outcomes varied among these ...

    Authors: Nai-Bin Chen, Mai Xiong, Rui Zhou, Yin Zhou, Bo Qiu, Yi-Feng Luo, Su Zhou, Chu Chu, Qi-Wen Li, Bin Wang, Hai-Hang Jiang, Jin-Yu Guo, Kang-Qiang Peng, Chuan-Miao Xie and Hui Liu
    Citation: Radiation Oncology 2022 17:184
    Content type: Research Published on:

  17. Besides featured glucose consumption, recent studies reveal that cancer cells might prefer “addicting” specific energy substrates from the tumor microenvironment (TME); however, the underlying mechanisms remai...

    Authors: Tongyan Liu, Chencheng Han, Panqi Fang, Zhifei Ma, Xiaoxiao Wang, Hao Chen, Siwei Wang, Fanchen Meng, Cheng Wang, Erbao Zhang, Guozhang Dong, Hongyu Zhu, Wenda Yin, Jie Wang, Xianglin Zuo, Mantang Qiu…
    Citation: Journal of Hematology & Oncology 2022 15:141
    Content type: Research Published on:

  18. Circulating tumor DNA (ctDNA) has been proven as a marker for detecting minimal residual diseases following systemic therapies in mid-to-late-stage non-small-cell lung cancers (NSCLCs) by multiple studies. How...

    Authors: Siwei Wang, Ming Li, Jingyuan Zhang, Peng Xing, Min Wu, Fancheng Meng, Feng Jiang, Jie Wang, Hua Bao, Jianfeng Huang, Binhui Ren, Mingfeng Yu, Ninglei Qiu, Houhuai Li, Fangliang Yuan, Zhi Zhang…
    Citation: Journal of Hematology & Oncology 2022 15:137
    Content type: Correspondence Published on:

  19. Solid tumors subjected to intermittent hypoxia are characterized by resistance to chemotherapy and immune-killing by effector T-lymphocytes, particularly tumor-infiltrating Vγ9Vδ2 T-lymphocytes. The molecular ...

    Authors: Iris C. Salaroglio, Dimas Carolina Belisario, Muhlis Akman, Sofia La Vecchia, Martina Godel, Dario Pasquale Anobile, Giacomo Ortone, Sabrina Digiovanni, Simona Fontana, Costanzo Costamagna, Menachem Rubinstein, Joanna Kopecka and Chiara Riganti
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:243
    Content type: Research Published on:

  20. Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation i...

    Authors: Jun Lu, Jun Wu, Yuqing Lou, Qin Shi, Jun Xu, Lele Zhang, Wei Nie, Jie Qian, Yanan Wang, Yanwei Zhang, Jing Jiao, Xueyan Zhang, Wei Zhang, Huimin Wang, Tianqing Chu, Hua Zhong…
    Citation: Biomarker Research 2022 10:55
    Content type: Research Published on:

  21. This retrospective study was performed to evaluate the efficacy and toxicity of high-dose stereotactic body radiotherapy (SBRT) using a CyberKnife® for patients with stage I peripheral non-small cell lung canc...

    Authors: Yasuhiro Ryuno, Takanori Abe, Misaki Iino, Satoshi Saito, Tomomi Aoshika, Tomohiro Oota, Mitsunobu Igari, Ryuta Hirai, Yu Kumazaki, Kyoichi Kaira, Hiroshi Kagamu, Hironori Ishida, Shin-ei Noda and Shingo Kato
    Citation: Radiation Oncology 2022 17:128
    Content type: Research Published on:

  22. To examine long-term-survival of cT4 cN0/1 cM0 non-small-cell lung carcinoma (NSCLC) patients undergoing definitive radiochemotherapy (ccRTx/CTx) in comparison to the trimodality treatment, neoadjuvant radiochemo...

    Authors: Nika Guberina, Christoph Pöttgen, Martin Schuler, Maja Guberina, Georgios Stamatis, Till Plönes, Martin Metzenmacher, Dirk Theegarten, Thomas Gauler, Kaid Darwiche, Clemens Aigner, Wilfried E. E. Eberhardt and Martin Stuschke
    Citation: Radiation Oncology 2022 17:126
    Content type: Research Published on:

  23. Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistanc...

    Authors: Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh and Tetsuya Mitsudomi
    Citation: Journal of Hematology & Oncology 2022 15:79
    Content type: Research Published on:

  24. Multiple lines of evidence have demonstrated that circular RNAs (circRNAs) play oncogenic or tumor-suppressive roles in various human cancers. Nevertheless, the biological functions of circRNAs in small cell l...

    Authors: Jinghan Hua, Xiaolin Wang, Liying Ma, Jingxin Li, Guozhen Cao, Shaobo Zhang and Wenchu Lin
    Citation: Molecular Cancer 2022 21:123
    Content type: Research Published on:

  25. Despite tremendous success of molecular targeted therapy together with immunotherapy, only a small subset of patients can benefit from them. Chemotherapy remains the mainstay treatment for most of tumors inclu...

    Authors: Yao Jiang, Wei Huang, Xiaojiao Sun, Xiaozhou Yang, Youming Wu, Jiaojiao Shi, Ji Zheng, Shujie Fan, Junya Liu, Jun Wang, Zhen Liang, Nan Yang, Zhenming Liu and Yanyong Liu
    Citation: Journal of Hematology & Oncology 2022 15:73
    Content type: Correspondence Published on:

  26. Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictiv...

    Authors: Diego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, Murat Ak, Feliciano Barron, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara-Mejia, Christine B. Peterson, Mehmet E. Er, Vishal Peddagangireddy, Francesco Buemi, Brandon Cooper, Paolo Manca, Rena G. Lapidus, Ru-Ching Hsia…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:186
    Content type: Research Published on:

  27. Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic chang...

    Authors: Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu…
    Citation: Journal of Hematology & Oncology 2022 15:62
    Content type: Correspondence Published on:

  28. Previous studies have confirmed the oncogenic role of HMGB2 in various cancers, but the biological functions of HMGB2-derived circRNAs remain unknown. Thus, we intended to investigate the potential role of HMG...

    Authors: Ling-Xian Zhang, Jian Gao, Xiang Long, Peng-Fei Zhang, Xin Yang, Shu-Qiang Zhu, Xu Pei, Bai-Quan Qiu, Shi-Wei Chen, Feng Lu, Kun Lin, Jian Jun Xu and Yong-Bing Wu
    Citation: Molecular Cancer 2022 21:110
    Content type: Research Published on:

  29. Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in firs...

    Authors: Lin Zhang, Weihao Lin, Fengwei Tan, Ning Li, Qi Xue, Shugeng Gao, Yibo Gao and Jie He
    Citation: Biomarker Research 2022 10:23
    Content type: Review Published on:

  30. Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The discovery of epidermal growth factor receptor (EGFR) gene mutations and the development of EGFR tyrosine kinase inhibi...

    Authors: Jiabao Hou, Hongle Li, Shuxiang Ma, Zhen He, Sen Yang, Lidan Hao, Hanqiong Zhou, Zhe Zhang, Jing Han, Li Wang and Qiming Wang
    Citation: Biomarker Research 2022 10:21
    Content type: Review Published on:

  31. VSports在线直播 -

    Lung cancer remains one of the major causes of cancer-related death globally. Recent studies have shown that aberrant m6A levels caused by METTL3 are involved in the malignant progression of various tumors, inclu...

    Authors: Chao Ma, Rui-Jie Ma, Kang Hu, Qi-Ming Zheng, Ye-Peng Wang, Nan Zhang and Zhi-Gang Sun
    Citation: Cancer Cell International 2022 22:133
    Content type: Review Published on:

  32. Autophagy has been found to be involved in the multidrug resistance (MDR) of cancers, but whether it is associated with resistance of small cell lung cancer (SCLC) has not been studied. Here, we hypothesized t...

    Authors: Tiezhi Li, Helin Zhang, Zhichao Wang, Shaolin Gao, Xu Zhang, Haiyong Zhu, Na Wang and Honglin Li
    Citation: Cancer Cell International 2022 22:120
    Content type: Primary research Published on:

  33. Online MR-guided radiotherapy (MRgRT) is a relatively novel advancement in the field of radiation oncology, ensuring superior soft-tissue visualisation, allowing for online plan adaptation to anatomical and fu...

    Authors: Chukwuka Eze, Elia Lombardo, Lukas Nierer, Yuqing Xiong, Maximilian Niyazi, Claus Belka, Farkhad Manapov and Stefanie Corradini
    Citation: Radiation Oncology 2022 17:43
    Content type: Short report Published on:

  34. Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). The mechanisms of osimertinib resistance need to be elucidated to determine...

    Authors: Xiaoying Wan, Boxiong Xie, Hui Sun, Weiqing Gu, Chunyan Wang, Qinfang Deng and Songwen Zhou
    Citation: Cancer Cell International 2022 22:83
    Content type: Primary research Published on:

  35. Approximately 50%–60% of secondary resistance to primary EGFR- tyrosine kinase inhibitors (TKI) therapy is caused by acquired p.Thr790Met (T790M) mutation; however, highly fragmented, low-quantity circulating tum...

    Authors: Boyeon Kim, Yoonjung Kim, Saeam Shin, Seung-Tae Lee, Jae Yong Cho and Kyung-A. Lee
    Citation: Cancer Cell International 2022 22:82
    Content type: Primary research Published on:

  36. Accurate predictions of tumor dissemination risks and medical treatment outcomes are critical to personalize therapy. Patient-derived xenograft (PDX) models in mice have demonstrated high accuracy in predictin...

    Authors: Zaheer Ali, Malin Vildevall, Gabriela Vazquez Rodriguez, Decky Tandiono, Ioannis Vamvakaris, Georgios Evangelou, Georgios Lolas, Konstantinos N. Syrigos, Alberto Villanueva, Michael Wick, Shenga Omar, Anna Erkstam, Julia Schueler, Anna Fahlgren and Lasse D. Jensen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:58
    Content type: Research Published on:

  37. Inflammation is a process that protects organs against various potentially harmful stimuli and enables repair. Dysregulated inflammation, however, damages tissues and leads to disease, including cancer. Cancer...

    Authors: Jun Zhang and Nirmal Veeramachaneni
    Citation: Biomarker Research 2022 10:5
    Content type: Review Published on:

  38. When genes responsible for normal embryonic development are abnormally expressed in adults, it can lead to tumor development. This can suggest that the same mechanism that controls embryonic differentiation ca...

    Authors: Jordi Canals, Alfons Navarro, Cristina Vila, Josep M. Canals, Tania Díaz, Melissa Acosta-Plasencia, Coralí Cros-Font, Bing Han, Yangyi He and Mariano Monzó
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:37
    Content type: Research Published on:

  39. Limited previous studies focused on the death and progression risk stratification of colorectal cancer (CRC) lung metastasis patients. The aim of this study is to construct a nomogram model combing machine lea...

    Authors: Renjie Wang, Weixing Dai, Jing Gong, Mingzhu Huang, Tingdan Hu, Hang Li, Kailin Lin, Cong Tan, Hong Hu, Tong Tong and Guoxiang Cai
    Citation: Journal of Hematology & Oncology 2022 15:11
    Content type: Letter to the Editor Published on:

  40. V体育官网入口 -

    Primary lung cancer is one of the most common malignant tumors in China. Approximately 60% of lung cancer patients have distant metastasis at the initial diagnosis, so it is necessary to find new tumor markers...

    Authors: Wen Li, Ji-Bin Liu, Li-Kun Hou, Fei Yu, Jie Zhang, Wei Wu, Xiao-Mei Tang, Feng Sun, Hai-Min Lu, Jing Deng, Jie Bai, Juan Li, Chun-Yan Wu, Qin-Lu Lin, Zhong-Wei Lv, Gao-Ren Wang…
    Citation: Molecular Cancer 2022 21:25
    Content type: Review Published on:

  41. Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durval...

    Authors: Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo and Akito Hata
    Citation: Radiation Oncology 2022 17:7
    Content type: Research Published on:

  42. N6-methyladenosine (m6A) has emerged as a significant regulator of the progress of various cancers. However, its role in lung adenocarcinoma (LUAD) remains unclear. Here, we explored the biological function and u...

    Authors: Yiming Xu, Dandan Lv, Chao Yan, Hua Su, Xue Zhang, Yangfeng Shi and Kejing Ying
    Citation: Cancer Cell International 2022 22:11
    Content type: Primary research Published on: